Hims may have an chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.

The Food and Drug Administration is considering lifting restrictions on some peptide injections.

There doesn't seem to be new safety or efficacy data, but Kennedy touts them anyway.

Hims may have an chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.

A physician examines whether the FDA's loosening of wellness peptide restrictions means these compounds are actually safe and proven. The answer may surprise you.